{"disease":{"id":"pseudomonas-infections","name":"pseudomonas infections"},"drugs":{"marketed":[{"drug_id":"colistimethate-sodium","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin M","generic_name":"COLISTIMETHATE SODIUM","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"colimycin","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"colimycin","company_name":"Poitiers University Hospital","drug_phase":"phase_1","molecular_target":"Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"colistin","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"COLISTIN","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Melanocortin receptor 3","drug_class":"colistin","quality_score":49,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03638830","title":"Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":777,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT07056881","title":"Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT03510351","title":"Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Temple University","has_results":false},{"nct_id":"NCT05210387","title":"Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections","phase":"NA","overall_status":"TERMINATED","enrollment_count":107,"lead_sponsor_name":"Hospital Moinhos de Vento","has_results":false},{"nct_id":"NCT06319235","title":"Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"MB PHARMA s.r.o.","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}